Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 5 at 2:00 PM EDT

Register Free →

FY26 FR0 DFS/PHL - Phenomenex testing supplies

Active
State & Local

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract titled FY26 FR0 DFS/PHL - Phenomenex testing supplies is a forecasted procurement under the Forensic Sciences (DFS) agency within the District of Columbia, aimed at securing testing supplies from Phenomenex for fiscal year 2026. Although the solicitation number is not yet assigned and no specific NAICS code, set-aside type, or organizational details are provided, the document indicates an intent to purchase specialized laboratory consumables and reagents likely used in forensic analysis. The place of performance and agency office address lack detailed location data, suggesting the procurement may support centralized or multiple forensic facilities across the district. The posting date of July 23, 2026, signals that this is a forward-looking planning notice, allowing vendors time to prepare for the upcoming solicitation. No point of contact information is listed, which may be updated when the formal request for proposals is issued. Interested parties should monitor the provided UI link for further details, as this forecast serves as an early indicator of anticipated spending and operational needs within the forensic program for the coming fiscal year.

General Info

Forecasted FY26 procurement for Phenomenex forensic testing supplies by DC DFS agency.

Agency

District of Columbia → Forensic Sciences (DFS)

NAICS

424210 - Drugs and Druggists' Sundries Merchant WholesalersView NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDistrict of Columbia → Forensic Sciences (DFS)
ContactsNo contacts available
OfficeN/A
Organization / Agency
District of Columbia → Forensic Sciences (DFS)
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Testing Supplies

Similar Contracts

Same NAICS industry code

NAICS: 424210
New
DIBBS
ALBUTEROL INHALATIOAlbuterol Inhalation Aerosol is a pressurized aluminum canister containing 60 actuations, each delivering 108 micrograms of albuterol sulfate, equivalent to 90 micrograms of albuterol base, via a plastic actuator with a strapcap and integrated counter. The product is prescribed for oral inhalation only and is classified as an institutional pack with a net canister weight of 8 grams. It must be stored at 20°C to 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F), and must always be kept with the mouthpiece down. The inhaler must be shaken well before each use and brought to room temperature prior to administration for optimal performance. The item has a non-extendable shelf life of 18 months, and at the time of receipt by the first government activity, it must have a minimum of 15 months of remaining shelf life. The product is hazardous due to its pressurized contents and flammable characteristics, and it must not be punctured, exposed to temperatures above 120°F, or disposed of in fire or incinerators. Packaging must comply with hazardous materials regulations including 49 CFR and ICAO standards, and a current Material Safety Data Sheet (MSDS) must accompany each shipment and be submitted via DLA’s designated email. Labeling and marking must adhere to SPE2DP-26-T-4242 and Medical Marking Standard No. 1C. The item is regulated by the FDA, and procurement requires referral confirmation through EBS. Packaging and technical requirements are governed by DLA specifications, including RD003, RA001, and RP001, and the NSN is 6505-01-649-7928. The purchase request is for 10 units with delivery expected within 20 days.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details
NAICS: 424210
New
DIBBS
PHARM MANUF/DISTR DIV - FSAThis contract establishes a nationwide pharmaceutical supply agreement under the Pharmaceutical Prime Vendor (PPV) program, managed by the Defense Logistics Agency Troop Support and the Department of Veterans Affairs, to provide essential medications to the Department of Defense, Veterans Affairs, Bureau of Prisons, and Indian Health Service. The awardee must supply listed pharmaceutical products in accordance with specified quantities estimated in Appendix B, with the contract structured for a one-year base period and four additional option years, totaling a maximum five-year term. Delivery is facilitated through designated PPV contractors, who receive products directly from the awardee and distribute them to government medical facilities; the contractor does not bill the government directly but instead enters into business-to-business agreements with each PPV for payment terms, delivery schedules, and logistics. The contractor is required to have all products registered with RXNorm, First Data Bank, and Medi-Span within five days of award and must comply with strict labeling standards including GS1-128 or HIBCC-compliant barcodes that encode the National Drug Code, lot number, and expiration date, with printing quality meeting ANSI/ISO/IEC Grade C or better. Packaging must feature child-proof closures, meet specific container dimensions, be compatible with automated dispensing systems, and exclude glass bottles. The solicitation is evaluated under a Lowest Price Technically Acceptable (LPTA) methodology, requiring technical acceptability in both compliance with the Statement of Work and demonstrated past performance before price is considered. Offers are deemed technically unacceptable if products lack FDA-approved NDA, ANDA, or BLA status, if manufacturing facilities have unresolved cGMP violations, or if therapeutic equivalence codes are not “A” rated unless all alternatives in the group are “B” rated with submitted bioequivalence data. The contractor must immediately report any FDA warning letters or cGMP inspection failures, and may be restricted from shipping affected products unless granted a 90-day authorization with an approved corrective action plan. Backorders occurring when orders are not fulfilled within 15 days trigger mandatory reporting within four calendar days and may lead to government procurement from alternate vendors, with the contractor liable for any excess costs incurred. The contractor is prohibited from assigning payment rights and cannot initiate claims under the Disputes Clause for disagreements with PPVs. Compliance with the Drug Supply Chain Security Act is mandatory, and adherence to DFARS 252.204-7018 prohibits the use of covered defense telecommunications equipment or services, requiring detailed disclosures of such equipment if applicable. All
MEDICAL SUPPLY CHAIN FSGB

POSTED

1 day ago

DEADLINE

in 29 days
View Details
NAICS: 424210
New
DIBBS
IOPAMIDOL INJECTIONIopamidol Injection, identified by NSN 6505-01-657-0664 and NDC 00270-1316-35, is a non-intrathecal contrast agent supplied in ten 100 mL single-dose bottles per package, with a shelf life of 24 months that is non-extendable and classified as a Type I Code M item. The product must be stored at 20 to 25°C (68 to 77°F) and protected from light, in compliance with USP standards. Packaging and marking must adhere strictly to Medical Marking Standard No. 1, which replaces all references to MIL-STD-129, and each unit must be sealed in a container that prevents damage or breakage, with outer shipping containers ensuring safe, cost-effective delivery via common carrier to the destination. The item is subject to Federal Acquisition Regulation requirements for medical acquisitions, including commercial packaging standards, and is classified under hazardous materials handling protocols due to its nature. Delivery is required FOB destination within five days of contract award, with zero tolerance for quantity variance, and inspection and acceptance occur at the delivery point. The contract, issued under solicitation SPE2DP-26-T-4236 by the Department of Defense’s Medical Supply Chain Pharmaceutical FSA, is for one package with delivery required by July 24, 2026, and is managed by Bracco Diagnostics Inc. with technical and quality requirements referenced from the DLA Master List. All logistics, labeling, and compliance must conform to DLA specifications, and the point of contact for inquiries is Timothy McCauley at DLA.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days
View Details